152351-91-2

Basic information

• Product Name: PYRIDINE, 3-BROMO-5-[[[(1,1-DIMETHYLETHYL)DIMETHYLSILYL]OXY]METHYL]-
• Synonyms: PYRIDINE, 3-BROMO-5-[[[(1,1-DIMETHYLETHYL)DIMETHYLSILYL]OXY]METHYL]-;3-bromo-5-((tert-butyldimethylsilyloxy)methyl)pyridine;(5-bromopyridin-3-yl)methoxy-tert-butyl-dimethylsilane
• CAS NO: 152351-91-2
• Molecular Formula: C₁₂H₂₀BrNOSi
• Molecular Weight: 302.286
• Mol File: 152351-91-2.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: PYRIDINE, 3-BROMO-5-[[[(1,1-DIMETHYLETHYL)DIMETHYLSILYL]OXY]METHYL]-(CAS DataBase Reference)
• NIST Chemistry Reference: PYRIDINE, 3-BROMO-5-[[[(1,1-DIMETHYLETHYL)DIMETHYLSILYL]OXY]METHYL]-(152351-91-2)
• EPA Substance Registry System: PYRIDINE, 3-BROMO-5-[[[(1,1-DIMETHYLETHYL)DIMETHYLSILYL]OXY]METHYL]-(152351-91-2)

Safety Data

• Hazardous Substances Data: 152351-91-2(Hazardous Substances Data)

Usage

General Description

PYRIDINE, 3-BROMO-5-[[[(1,1-DIMETHYLETHYLETHYL)DIMETHYLSILYL]OXY]METHYL]- is a chemical compound primarily used in the field of synthetic chemistry. Its structure consists of a pyridine ring, a common component in many organic molecules, which is substituted with bromine and a complex silyl ether group. The silyl ether part comprises of a silyl group, a class of organosilicon compounds, attached to an oxygen molecule. The inclusion of bromine suggests that the compound may be reactive and useful for making other compounds. The compound is likely to be synthesized in the laboratory with potential applications in pharmaceuticals, agrochemicals, or materials science. However, specific information about its toxicity or potential for environmental harm would primarily depend on additional research.

Upstream product

• 29681-44-5 5-bromo-3-pyridine carboxylic acid methyl ester 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 22620-36-6 3-bromo-5-(hydroxymethyl)pyridine hydrochloride 
• 20826-04-4 5-bromo-3-pyridinecarboxylic acid 
• 37669-64-0 (5-bromopyridin-3-yl)methanol 
• 69739-34-0 t-butyldimethylsiyl triflate 

Downstream Products

• 173999-08-1 5-(tert-butyldimethylsilanyloxy-methyl)pyridine-3-boronic acid 
• 1033125-26-6 [5-(tert-butyl-dimethyl-silanyloxymethyl)-pyridin-3-yl]-(4-fluoro-phenyl)-methanone 
• 289677-67-4 di-tert-butyl N-{4-[5-[(2,4-diamino-6(1H)-pyrimidinon-5-yl)thiomethyl]-3-pyridinyl]benzoyl}-L-glutamate 
• 289677-40-3 di-tert-butyl N-{4-[5-[(2,4-diamino-6(1H)-pyrimidinon-5-yl)methyl]-3-pyridinyl]benzoyl}-L-glutamate 
• 289677-65-2 4-[5-(2,4-diamino-6-oxo-1,6-dihydro-pyrimidin-5-ylsulfanylmethyl)-pyridin-3-yl]-benzoic acid methyl ester 
• 443964-36-1 5-azidopyridin-3-ylmethyl chloride 
• 289677-34-5 methyl 4-[5-[[[(1,1-dimethylethyl)silyl]oxy]methyl]-3-pyridinyl]benzoate 

Relevant articles and documents

A predictive model for additions to: N -alkyl pyridiniums

Disclosed in this communication is a thorough study on the dearomative addition of organomagnesium nucleophiles to N-alkyl pyridinium electrophiles. The regiochemical outcomes have observable and predictable trends associated with the substituent patterns on the pyridinium electrophile. Often, the substituent effects can be either additive, giving high selectivities, or ablative, giving competing outcomes. Additionally, the nature of the organometallic nucleophilic component was also investigated for its role in the regioselective outcome. The effects of either reactive component are important to both the overall reactivity and site of nucleophilic addition. The utility of these observed trends is demonstrated in a concise, dearomative synthesis of a tricyclic compound shown to have insecticidal activity. This journal is

PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS

The present invention relates to a novel class of phosphorus derivatives. The phosphorus compounds can be used to treat cancer. The phosphorus compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differe

TRIAZOLO-PYRIDAZINE COMPOUNDS AND DERIVATIVES THEREOF USEFUL IN THE TREATMENT OF NEUROPATHIC PAIN

The present invention is directed to a method of use of triazolo-pyridazine compounds in the treatment of neuropathic pain. The present invention is also directed to the use of triazolo-pyridazine compounds in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson’s disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders - such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal and other diseases. The present invention is also directed to novel triazolo-pyridazine compounds that selectively bind to α2δ-1 subunit of Ca channels.